{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:03:45Z","timestamp":1793714625206,"version":"4.6.1"},"reference-count":44,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited data exist on the comparative risk of infections during biologic and Janus kinase inhibitor (JAKi) treatment for atopic dermatitis (AD) in daily practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the differential infection risk of biologic and JAKi treatment in patients with moderate\u2010to\u2010severe AD in a real\u2010world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicentre study evaluated treatment\u2010emergent infections in patients (age\u2009\u2265\u200912\u2009years) using biologics or JAKi from the BioDay registry from October 2017 to July 2024. Crude incidence rates were calculated per 100 patient\u2010years (PY) per treatment. Cox regression for recurrent events, adjusted for potential confounders, was used to estimate hazard ratios (HR) for the rate of infections, with subgroup and sensitivity analyses in bio\u2010\/JAKi\u2010na\u00efve patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total 1793 patients were included (4044.1 PY; 1886 biologic treatment episodes (TEs); 480 JAKi), with 794 infections. JAKi showed higher infection rates (58.4\u201365.5\/100 PY) compared to biologics (13.6\u201322.0), especially for herpes infections (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009195, 24.6%; JAKi 13.6\u201319.8 vs. biologicals 3.0\u20133.6). Cox regression indicated increased rates with JAKi (abrocitinib HR 4.1, 95% CI: 3.1\u20135.5; baricitinib HR 4.2, 95% CI: 2.9\u20136.2; upadacitinib HR 4.0, 95% CI: 3.2\u20135.0; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and a slight increase with tralokinumab (HR 1.4, 95% CI: 1.0\u20132.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039) compared to dupilumab. Sensitivity analyses confirmed these results, except for tralokinumab. Rates of severe infections were higher with JAKi compared to dupilumab, although absolute numbers were low and associations were not consistently significant. History of infection, predominantly viral or fungal skin infections (HR 1.9, 95% CI: 1.4\u20132.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001; 2.4, 1.3\u20134.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003, resp.), was identified as an independent factor associated with infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This cohort study demonstrated an increased risk of infection during JAKi treatment compared to dupilumab for moderate\u2010to\u2010severe AD. These findings enhance understanding of the differential infection risk with targeted therapies in AD, aiding tailored treatment choices that consider patient\u2010specific risks such as prior skin infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.20674","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:17:44Z","timestamp":1743783464000},"page":"2056-2068","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Infection risk in atopic dermatitis patients treated with biologics and\n                    <scp>JAK<\/scp>\n                    inhibitors:\n                    <scp>BioDay<\/scp>\n                    results"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-7771","authenticated-orcid":false,"given":"Lian F.","family":"van der Gang","sequence":"first","affiliation":[{"name":"National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keneshka","family":"Atash","sequence":"additional","affiliation":[{"name":"National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaas P. A.","family":"Zuithoff","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Haeck","sequence":"additional","affiliation":[{"name":"National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3371-6414","authenticated-orcid":false,"given":"Celeste M.","family":"Boesjes","sequence":"additional","affiliation":[{"name":"National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavian I.","family":"Baco\u015f\u2010Cosma","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-9284","authenticated-orcid":false,"given":"Laura","family":"Loman","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Kamsteeg","sequence":"additional","affiliation":[{"name":"Department of Dermatology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Stadhouders\u2010Keet","sequence":"additional","affiliation":[{"name":"Department of Dermatology Reinier de Graaf Hospital  Delft The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Oosting","sequence":"additional","affiliation":[{"name":"Department of Dermatology Spaarne Gasthuis  Hoofddorp The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke M. T.","family":"van Lynden\u2010van Nes","sequence":"additional","affiliation":[{"name":"Department of Dermatology Meander Medical Center  Amersfoort The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaziena","family":"Politiek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Center Leeuwarden  Leeuwarden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-2914","authenticated-orcid":false,"given":"Antoni","family":"Gostynksi","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Maastricht  Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Berntsen\u2010Zandbergen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Haga Hospital  Den Haag The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wianda A.","family":"Christoffers","sequence":"additional","affiliation":[{"name":"Department of Dermatology Isala Hospital  Zwolle The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annebeth","family":"Flinterman","sequence":"additional","affiliation":[{"name":"Department of Dermatology Diakonessenhuis  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter R. H.","family":"Touwslager","sequence":"additional","affiliation":[{"name":"Department of Dermatology Catharina Hospital  Eindhoven The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"Velstra","sequence":"additional","affiliation":[{"name":"Department of Dermatology St. Antonius Hospital  Nieuwegein The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiarra M.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Dermatology IJsselland Hospital  Capelle aan den IJssel The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine C.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Dermatology TerGooi Medical Center  Hilversum The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[{"name":"National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Louise A.","family":"Schuttelaar","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein S.","family":"de Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology University Medical Center Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.019"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8548-5"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000526"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.07.111"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068582"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.028"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.002"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20887"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.029"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0455"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19426"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010024\u201001203\u20102"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.064"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.07.019"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113383"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.08.034"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad159"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_14_20_1","unstructured":"U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.2017[updated November 27 2017]. Available from:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199901000-00008"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1816"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-2555-1"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12982\u2010017\u20100060\u20108"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/69.1.239"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-68560-1"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10705510802339072"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-007-0070-9"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.21558"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.433"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.22237\/jmasm\/1608552120"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0338-0"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.1.27"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19643"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.09.052"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.05.026"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.08.024"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)31191\u20101"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.069"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu222"},{"key":"e_1_2_14_44_1","unstructured":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [press release]. 28 October 2022."},{"key":"e_1_2_14_45_1","unstructured":"FDA requires warnings about increased risk of serious heart\u2010related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions [press release]. 12 July 2021."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20674","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.20674","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20674","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:28:37Z","timestamp":1772969317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/jdv.20674"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20674","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}